Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology
- 7 February 2015
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 102 (1) , 108-113
Abstract
Aim: To assess patient perception toward oral chemotherapy for solid tumors, the Italian Association of Medical Oncology performed a large multi-institutional national survey. Methods: A 17-item anonymous questionnaire including 7 general and 10 investigational questions with free-text, single-choice, or multiple-choice answers was administered. Analysis of response distribution according to predefined factors was described by summary measures and conducted by χ2 test and other nonparametric tests. Results: From January to June 2010, 581 patients completed the questionnaire; data of 404 patients constituted the final study sample. Three groups could be distinguished according to treatment: IV chemotherapy (IV group, n = 313), oral chemotherapy (oral group, n = 48), or combined therapy (combined group, n = 43). Thirty-one (72%) patients in the combined group and 187 (60%) in the IV group expressed preference for oral therapy (p = 0.028). Limitations in family and work commitment were more frequently perceived by patients on IV than oral chemotherapy (147 (47%) vs 14 (29%) patients, p<0.05, and 134 (43%) vs 11 (23%) patients, p<0.05). A total of 134 (43%) patients on IV chemotherapy versus 15 (31%) patients in the oral group did not point out any limitation for number of tablets per day (p = 0.004). Conclusions: We observed a propensity from the patient perspective in favor of oral chemotherapy that was considered to have a lower impact on family and work commitments than IV chemotherapy. The treatment that patients were taking when the questionnaire was administered likely influenced their perception and related results.Keywords
This publication has 8 references indexed in Scilit:
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES StudyJournal of Clinical Oncology, 2014
- Anticancer oral therapy: Emerging related issuesCancer Treatment Reviews, 2010
- Do people with cancer comply with oral chemotherapy treatments?British Journal of Community Nursing, 2006
- A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerAnnals of Oncology, 2005
- Perception that Oral Anticancer Treatments are Less Efficacious: Development of a Questionnaire to Assess the Possible Prejudices of Patients with CancerBreast Cancer Research and Treatment, 2005
- Adherence to Therapy With Oral Antineoplastic AgentsJNCI: Journal of the National Cancer Institute, 2002
- Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorinEuropean Journal of Cancer, 2002
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997